Stay updated with breaking news from Philippe Genne. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regulatory News: Oncodesign Precision Medicine , a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, today announced that Degroof...
Nomination of Florence Dupré as a member of the Board of Directors Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing
Revenues and operating income in 2022 of €8.3 M (+110% vs. 2021 proforma), including revenues of €8 M, mainly driven by a €7 M milestone and a €0.5 M up-frontNet income almost at break-even (€0.2) MStrong financial visibility with a cash position of €13.4 M ensuring the development of our programs for the coming yea...
Revenues and operating income in 2022 of €8.3 M (+110% vs. 2021 proforma), including revenues of €8 M, mainly driven by a €7 M milestone and a €0.5 M up-front Net income almost at break-even
First-in-Man study of ODS-101 in healthy volunteersDIJON, France--(BUSINESS WIRE)--Regulatory News:Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM) (Paris:ALOPM), a clinical stage biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cance...